← Back to All US Stocks

Healthy Extracts Inc.. (HYEX) Stock Fundamental Analysis & AI Rating 2026

HYEX OTC Medicinal Chemicals & Botanical Products NV CIK: 0001630176
Recently Updated • Analysis: Apr 11, 2026 • SEC Data: 2025-12-31
Combined AI Rating
SELL
78% Confidence
AGREEMENT
STRONG SELL
85% Conf
SELL
72% Conf

📊 HYEX Key Takeaways

Revenue: $4.5M
Net Margin: 446.0%
Free Cash Flow: $165.5K
Current Ratio: 0.79x
Debt/Equity: 0.03x
EPS: $0.00
AI Rating: STRONG SELL with 85% confidence
Healthy Extracts Inc.. (HYEX) receives a SELL rating with 78% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $4.5M, net profit margin of 446.0%, and return on equity (ROE) of 83.7%, Healthy Extracts Inc.. demonstrates mixed fundamentals in the Materials sector. Below is our complete HYEX stock analysis for 2026.

Is Healthy Extracts Inc.. (HYEX) a Good Investment?

Claude

Despite exceptional 2245% revenue growth and healthy 53.7% gross margins, the company's core operations are severely unprofitable at -73.7% operating margin. The 20.1M net income with zero YoY growth appears driven by non-operating items rather than sustainable operations. Critical liquidity constraints (0.79x current ratio, only 146.9K cash) combined with negative operating cash breakeven create acute financial distress.

ChatGPT

Revenue surged with a solid gross margin, but core operations remain deeply unprofitable and cash-constrained. The outsized net income and high ROE/ROA appear driven by non-operating items, masking weak operating performance and negative interest coverage. Without clear, recurring operating profitability and improved liquidity, downside fundamental risk dominates.

Why Buy Healthy Extracts Inc.. Stock? HYEX Key Strengths

Claude
  • + Exceptional YoY revenue growth of 2245.7% demonstrates strong market demand and commercial traction
  • + Healthy gross margin of 53.7% indicates product-market fit and pricing power
  • + Low debt-to-equity ratio of 0.03x minimizes financial leverage and default risk
ChatGPT
  • + Rapid revenue growth off a small base
  • + Healthy gross margin (~54%) indicating product economics
  • + Low leverage with modest long-term debt

HYEX Stock Risks: Healthy Extracts Inc.. Investment Risks

Claude
  • ! Operating margin of -73.7% reveals core business is fundamentally unprofitable despite revenue growth
  • ! Critical liquidity crisis with current ratio 0.79x and minimal 146.9K cash reserves creates solvency risk
  • ! Net income of 20.1M with 0.0% YoY growth indicates reliance on non-operating items, not operational profitability
  • ! Interest coverage ratio of -41.6x shows inability to service debt from operational earnings
  • ! Zero insider buying activity in 90 days suggests management lacks confidence in fundamentals
ChatGPT
  • ! Liquidity stress (current ratio 0.79x, minimal cash)
  • ! Sustained operating losses and negative interest coverage
  • ! Earnings quality risk from likely one-time/non-cash gains inflating net income

Key Metrics to Watch

Claude
  • * Operating margin trajectory - must turn positive to validate business model sustainability
  • * Cash balance and burn rate - immediate solvency threat given liquidity ratios
  • * Operating cash flow consistency - validate if 165.5K FCF is repeatable or one-time
ChatGPT
  • * Operating margin (recurring)
  • * Current ratio

Healthy Extracts Inc.. (HYEX) Financial Metrics & Key Ratios

Revenue
$4.5M
Net Income
$20.1M
EPS (Diluted)
$0.00
Free Cash Flow
$165.5K
Total Assets
$27.8M
Cash Position
$146.9K

💡 AI Analyst Insight

The relatively thin 3.7% FCF margin may limit capital allocation flexibility. The current ratio below 1.0x warrants monitoring of short-term liquidity.

HYEX Profit Margin, ROE & Profitability Analysis

Gross Margin 53.7%
Operating Margin -73.7%
Net Margin 446.0%
ROE 83.7%
ROA 72.3%
FCF Margin 3.7%

HYEX vs Materials Sector: How Healthy Extracts Inc.. Compares

How Healthy Extracts Inc.. compares to Materials sector averages

Net Margin
HYEX 446.0%
vs
Sector Avg 10.0%
HYEX Sector
ROE
HYEX 83.7%
vs
Sector Avg 14.0%
HYEX Sector
Current Ratio
HYEX 0.8x
vs
Sector Avg 1.6x
HYEX Sector
Debt/Equity
HYEX 0.0x
vs
Sector Avg 0.6x
HYEX Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Healthy Extracts Inc.. Stock Overvalued? HYEX Valuation Analysis 2026

Based on fundamental analysis, Healthy Extracts Inc.. appears fundamentally strong relative to the Materials sector in 2026.

Return on Equity
83.7%
Sector avg: 14%
Net Profit Margin
446.0%
Sector avg: 10%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.03x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Healthy Extracts Inc.. Balance Sheet: HYEX Debt, Cash & Liquidity

Current Ratio
0.79x
Quick Ratio
0.29x
Debt/Equity
0.03x
Debt/Assets
13.6%
Interest Coverage
-41.57x
Long-term Debt
$641.9K

HYEX Revenue & Earnings Growth: 5-Year Financial Trend

HYEX 5-year financial data: Year 2021: Revenue $1.7M, Net Income -$2.6M, EPS N/A. Year 2022: Revenue $2.3M, Net Income -$2.0M, EPS N/A. Year 2023: Revenue $2.5M, Net Income -$983.1K, EPS N/A. Year 2024: Revenue $3.1M, Net Income -$2.5M, EPS N/A. Year 2025: Revenue $4.5M, Net Income -$840.7K, EPS N/A.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Healthy Extracts Inc..'s revenue has grown significantly by 169% over the 5-year period, indicating strong business expansion.

HYEX Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
3.7%
Free cash flow / Revenue

HYEX Quarterly Earnings & Performance

Quarterly financial performance data for Healthy Extracts Inc.. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $744.9K $354.5K N/A
Q2 2025 $908.4K $67.1K N/A
Q1 2025 $688.8K -$398.9K N/A
Q3 2024 $613.5K -$247.9K N/A
Q2 2024 $588.5K $113.5K N/A
Q1 2024 $614.9K -$579.2K N/A
Q3 2023 $499.7K -$170.2K N/A
Q2 2023 $469.8K -$856.3K N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Healthy Extracts Inc.. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
$165.5K
Cash generated from operations
Dividends
None
No dividend program

HYEX SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Healthy Extracts Inc.. (CIK: 0001630176)

📋 Recent SEC Filings

Date Form Document Action
Apr 9, 2026 10-K hyex-20251231_10k.htm View →
Nov 14, 2025 10-Q hyex-20250930_10q.htm View →
Oct 2, 2025 8-K hyex-20250926_8k.htm View →
Sep 23, 2025 8-K hyex-20250916_8k.htm View →
Aug 22, 2025 4 xslF345X05/form4.xml View →

Frequently Asked Questions about HYEX

What is the AI rating for HYEX?

Healthy Extracts Inc.. (HYEX) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are HYEX's key strengths?

Claude: Exceptional YoY revenue growth of 2245.7% demonstrates strong market demand and commercial traction. Healthy gross margin of 53.7% indicates product-market fit and pricing power. ChatGPT: Rapid revenue growth off a small base. Healthy gross margin (~54%) indicating product economics.

What are the risks of investing in HYEX?

Claude: Operating margin of -73.7% reveals core business is fundamentally unprofitable despite revenue growth. Critical liquidity crisis with current ratio 0.79x and minimal 146.9K cash reserves creates solvency risk. ChatGPT: Liquidity stress (current ratio 0.79x, minimal cash). Sustained operating losses and negative interest coverage.

What is HYEX's revenue and growth?

Healthy Extracts Inc.. reported revenue of $4.5M.

Does HYEX pay dividends?

Healthy Extracts Inc.. does not currently pay dividends.

Where can I find HYEX SEC filings?

Official SEC filings for Healthy Extracts Inc.. (CIK: 0001630176) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is HYEX's EPS?

Healthy Extracts Inc.. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is HYEX a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Healthy Extracts Inc.. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is HYEX stock overvalued or undervalued?

Valuation metrics for HYEX: ROE of 83.7% (sector avg: 14%), net margin of 446.0% (sector avg: 10%). Higher ROE suggests strong returns relative to peers.

Should I buy HYEX stock in 2026?

Our dual AI analysis gives Healthy Extracts Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.

What is HYEX's free cash flow?

Healthy Extracts Inc..'s operating cash flow is $165.5K, with capital expenditures of $0.0. FCF margin is 3.7%.

How does HYEX compare to other Materials stocks?

Vs Materials sector averages: Net margin 446.0% (avg: 10%), ROE 83.7% (avg: 14%), current ratio 0.79 (avg: 1.6).

Why is HYEX's return on equity (ROE) so high?

Healthy Extracts Inc.. has a return on equity of 83.7%, significantly above the Materials sector average of 14%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 446.0% net margin.

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Browse: High ROE Stocks
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 11, 2026 | Data as of: 2025-12-31 | Powered by Claude AI